Skip to Content

Join the 'Xgeva' group to help and get support from people like you.

Xgeva News

Breast Cancer Drugs Battle Disease's Return

Posted 9 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 9, 2015 – A pair of drugs already on the market appear to reduce the recurrence of breast cancer in women who've already undergone treatment, two new clinical trials show. The chemotherapy drug capecitabine (Afinitor) seems to reduce by nearly a third the risk of breast cancer recurrence if women receive the drug following surgery to remove their cancer, researchers were to report Wednesday at the 2015 San Antonio Breast Cancer Symposium. In addition, an osteoporosis medication called denosumab appears to reduce recurrence risk by 18 percent in women who have HR-positive breast cancer, a second study reports. Denosumab (Xgeva) is usually given to women undergoing breast cancer treatment because hormone therapy for their disease can make their bones brittle, explained lead researcher Dr. Michael Gnant, a professor of surgery at the Medical University of Vienna in ... Read more

Related support groups: Breast Cancer, Osteoporosis, Prolia, Fracture, bone, Xeloda, Breast Cancer - Adjuvant, Xgeva, Breast Cancer, Prevention, Capecitabine, Denosumab

Strong Bones After 50? Women May Not Need Next Test Until 65

Posted 9 Jun 2015 by Drugs.com

TUESDAY, June 9, 2015 – A postmenopausal woman who is 50 and still shows "normal" readings on her bone density test may not need her next such test for 10 or even 15 years, a new study finds. However, researchers led by Dr. Margaret Gourlay of the University of North Carolina at Chapel Hill stressed that younger women who do show signs of bone loss are at high risk for a major fracture, and do require regular testing. The study involved almost 4,100 postmenopausal American women between the ages of 50 and 64 who took part in the ongoing Women's Health Initiative study. All of the women had undergone a bone mineral density test to assess their risk for fractures and osteoporosis. The women were not taking hormones, calcium or vitamin D supplements. They also had never had a broken bone, the team said. The results: Among women whose tests showed no signs of osteoporosis, it took nearly ... Read more

Related support groups: Hot Flashes, Menopausal Disorders, Osteoporosis, Fosamax, Postmenopausal Symptoms, Boniva, Alendronate, Prolia, Reclast, Fracture, bone, Actonel, Prevention of Osteoporosis, Zometa, Xgeva, Aclasta, Zoledronic Acid, Atelvia, Ibandronate, Risedronate, Caltrate 600 with D

FDA Approves Xgeva (denosumab) for Hypercalcemia of Malignancy Refractory to Bisphosphonate Therapy

Posted 8 Dec 2014 by Drugs.com

THOUSAND OAKS, Calif., Dec. 8, 2014 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Xgeva (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. Xgeva was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. HCM is a serious complication in patients with advanced cancer, including those with hematologic malignancies, and indicates poor prognosis.1,2 The condition results from cancer-driven increases in bone resorption, and if untreated, can lead to renal failure, progressive mental impairment, coma and death.1-3 "Our continued study of Xgeva reinforces Amgen's ongoing commitment to address the unmet needs of cancer ... Read more

Related support groups: Xgeva, Hypercalcemia of Malignancy, Denosumab

Osteoporosis Drugs Work, But Review Finds No Clear Winner

Posted 8 Sep 2014 by Drugs.com

MONDAY, Sept. 8, 2014 – Many osteoporosis drugs cut women's risk of suffering a bone fracture, though it's not clear whether any one medication works better than others, a new research review finds. Reporting Sept. 8 in Annals of Internal Medicine, researchers said that for women with the bone-thinning disease osteoporosis, various drugs cut the risk of a spine fracture by 40 to 60 percent, compared to a placebo. When it comes to other bone breaks, including hip fractures, the drugs lower the risk by 20 to 40 percent, the study said. The beneficial drugs included bisphosphonates, sold under brand names such as Actonel (risedronate), Boniva (ibandronate) and Fosamax (alendronate), and the injection drugs denosumab (Prolia) and teriparatide (Forteo). Meanwhile, raloxifene (Evista) – a daily pill that has estrogen-like effects on bones – seems to cut the risk of spine fractures only, ... Read more

Related support groups: Osteoporosis, Forteo, Fosamax, Boniva, Alendronate, Prolia, Reclast, Fracture, bone, Actonel, Evista, Prevention of Osteoporosis, Zometa, Xgeva, Aclasta, Zoledronic Acid, Atelvia, Risedronate, Ibandronate, Teriparatide, Raloxifene

FDA Approves Xgeva to Treat Giant Cell Tumor of the Bone

Posted 13 Jun 2013 by Drugs.com

June 13, 2013 – The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor. GCTB generally occurs in adults between the ages of 20 and 40 years. In most cases, GCTB does not spread to other parts of the body but destroys normal bone as it grows, causing pain, limited range of motion and bone fractures. Rarely, GCTB can transform into a cancerous tumor and spread to the lungs. Xgeva is a monoclonal antibody that binds to RANKL, a protein essential for maintenance of healthy bone. RANKL is also present in GCTB. Xgeva is intended for patients whose GCTB cannot be surgically removed (unresectable) or when surgery is likely to result in severe morbidity, such as loss of limbs or joint removal. It should only be used in adolescents whose ... Read more

Related support groups: Xgeva, Denosumab

Xgeva Approved for Rare, Non-Malignant Tumor

Posted 13 Jun 2013 by Drugs.com

THURSDAY, June 13 – Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous. The tumor usually affects adults between ages 20 and 40, although it may also develop in adolescents, the FDA said Thursday in a news release. It typically doesn't spread, although in rare cases it can become cancerous and travel to the lungs. As a non-cancerous tumor, GCTB destroys bone as it becomes larger, causing pain, fractures and loss of mobility. Xgeva has been approved in cases where the tumor can't be surgically removed, or might lead to a severe outcome such as loss of a limb, the agency said. Xgeva, approved under the FDA's expedited review program, was evaluated for this use in two clinical trials involving a total of 305 adults and adolescents. Common side effects included joint pain, ... Read more

Related support groups: Xgeva

Combo Drug Therapy May Work Best to Strengthen Bones: Study

Posted 14 May 2013 by Drugs.com

TUESDAY, May 14 – A new combination drug therapy for osteoporosis appears to increase bone density more effectively than any treatment now on the market, according to the results of a small clinical trial. Researchers found that postmenopausal women experienced significant amounts of bone growth by taking a bone-building drug called teriparatide with denosumab, a targeted therapy drug used to stop bone loss. "A combination of these two medications increased bone density more than either does on its own, and it is more effective than any currently approved therapy," said study author Dr. Benjamin Leder, who is with the endocrine unit at Massachusetts General Hospital in Boston. The 12-month study, published online May 15 in The Lancet, was funded in part by the drugs' makers, Eli Lilly and Amgen. It involved 94 postmenopausal women being treated for osteoporosis, a bone-thinning ... Read more

Related support groups: Osteoporosis, Forteo, Prolia, Xgeva, Teriparatide, Denosumab

Newer Bone Drug Better for Advanced Breast Cancer Patients: Study

Posted 14 Aug 2012 by Drugs.com

TUESDAY, Aug. 14 – The relatively new drug denosumab (Xgeva) reduces bone complications of advanced breast cancer more effectively than another osteoporosis drug, zoledronic acid (Zometa), according to new research. Zoledronic acid belongs to a class of drugs known as bisphosphonates, which help delay bone complications such as fractures, spinal cord compression and bone pain. But zoledronic acid has been linked with kidney toxicity and other reactions. Denosumab, a newer drug called a monoclonal antibody, is superior to zoledronic acid in reducing skeletal problems and better tolerated, the study found. "It's more effective at preventing bone destruction caused by breast cancer that has spread to the bone," said Dr. Alison Stopeck, associate professor of medicine at the University of Arizona, Tucson, and an investigator on the study, which was published Aug. 14 in the journal Clinical ... Read more

Related support groups: Fosamax, Boniva, Alendronate, Prolia, Reclast, Actonel, Zometa, Xgeva, Aclasta, Zoledronic Acid, Atelvia, Ibandronate, Risedronate, Pamidronate, Fosamax Plus D, Aredia, Denosumab, Skelid, Osteolytic Bone Metastases of Breast Cancer, Etidronate

Newer Drug May Help Prevent Fracture in Men With Prostate Cancer

Posted 25 Feb 2011 by Drugs.com

WEDNESDAY, Feb. 23 – A new drug called denosumab (Xgeva) performed somewhat better than the current standard treatment of zoledronic acid (Zometa) for preventing fractures and other bone problems in men with hormone-resistant prostate cancer, a new study suggests. In many patients, prostate cancer becomes resistant to initial hormone treatment within the first few years of diagnosis. As a result, tumors begin to grow again and spread to other parts of the body, including bones. This increases the risk of fractures and other bone problems that cause pain and disability, which can greatly reduce a man's quality of life, according to background information in the study. Helping to prevent these bone troubles can prove very important to these patients, one expert said. "The successful treatment of osteoporosis, bone pain, and complications of advanced boney disease in men with ... Read more

Related support groups: Prostate Cancer, Prolia, Xgeva, Denosumab

Ask a Question

Further Information

Related Condition Support Groups

Osteolytic Bone Metastases of Solid Tumors, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy

Xgeva Patient Information at Drugs.com